These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20394185)

  • 1. Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome.
    Feinberg SS
    CNS Spectr; 2010 Jan; 15(1):53-5. PubMed ID: 20394185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
    Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
    Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
    Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU
    Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.
    Nichols AI; Tourian KA; Tse SY; Paul J
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1565-74. PubMed ID: 21067460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desvenlafaxine: a new antidepressant or just another one?
    Pae CU
    Expert Opin Pharmacother; 2009 Apr; 10(5):875-87. PubMed ID: 19351235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desvenlafaxine in the treatment of major depressive disorder.
    Pae CU
    Expert Opin Pharmacother; 2011 Dec; 12(18):2923-8. PubMed ID: 22098230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desvenlafaxine succinate for major depressive disorder.
    Sproule BA; Hazra M; Pollock BG
    Drugs Today (Barc); 2008 Jul; 44(7):475-87. PubMed ID: 18806899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
    Kamath J; Handratta V
    Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
    Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
    Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
    Xu Y; Bai SJ; Lan XH; Qin B; Huang T; Xie P
    Braz J Med Biol Res; 2016 May; 49(6):. PubMed ID: 27240293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor].
    Alcantara-Montero A
    Rev Neurol; 2017 Mar; 64(5):219-226. PubMed ID: 28229443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder.
    Clayton AH; Kornstein SG; Rosas G; Guico-Pabia C; Tourian KA
    CNS Spectr; 2009 Apr; 14(4):183-95. PubMed ID: 19407730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
    Eckert L; Lançon C
    BMC Psychiatry; 2006 Jul; 6():30. PubMed ID: 16867188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.